cbdMD, Inc. YCBD
0.47
0.01
2.17%
as of 25 Sep
- Market cap
- $4.8M
- P/E
- 55.3×
Follow YCBD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(95.30%) | (68.90%) | (62.55%) | (43.01%) | |
| (41.67%) | (31.85%) | (26.82%) | (26.73%) | ||
ROIC |
(27.22%) | (26.27%) | (25.18%) | (29.78%) | |
Return on Tangible Assets |
(120.37%) | (64.28%) | (53.84%) | (62.19%) | |
Average Days of Receivables |
19.80 | 21.36 | 28.73 | 30.56 | |
Free Cash Flow per Share |
(0.41) | (0.24) | (0.25) | (0.23) | |
Free Cash Flow |
(1.64) | (2.13) | (2.65) | (2.41) | |
Capital Expenditures |
(0.18) | (0.18) | (0.17) | (0.19) | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
(15.31%) | (15.71%) | (20.80%) | (21.47%) | |
Accounts Receivable Turnover |
18.96 | 15.98 | 15.23 | 15.39 | |
Accounts Payable Turnover |
5.32 | 7.37 | 6.06 | 6.54 | |
Inventory Turnover |
2.83 | 2.95 | 2.71 | 2.92 | |
Average Days of Payables |
59.31 | 42.73 | 62.65 | 61.49 | |
Days of Inventory on Hand |
138.07 | 144.54 | 149.32 | 135.08 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.45% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.52 | 0.80 | 0.72 | |
Depreciation/Fixed assets |
6.47 | 4.83 | 4.76 | 5.12 | |
Capex/Depreciation |
(0.10) | (0.10) | (0.10) | (0.11) | |
Revenue per Share |
4.77 | 2.12 | 1.91 | 1.97 | |
Operating CF per Share |
(0.36) | (0.22) | (0.24) | (0.21) | |
Capex per Share |
(0.05) | (0.02) | (0.02) | (0.02) | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(22.80%) | (19.45%) | (15.56%) | (14.71%) |
Columns are period end dates